Our first product will be a hand-held respiratory viral test panel, enabling at home molecular detection and multiplexed identification of Flu-A/B/RSV/SARS-CoV-2 from a self-collected saliva sample, achieving portable state-of-the-art sensitivity and specificity. The safe sealed test cartridge will eliminate the risks due to sample handling and shipping to laboratories. Self-tests for HIV-Viral Load and other infectious diseases and pathogens will follow. Immediate encrypted digital wireless upload of results will enable real-time epidemiological tracking.

We are a team of twenty scientists engineers, including nine PhDs, has for the past seven years been researching and developing a Bioorthogonal alternative to PCR. With minimal sample preparation, the Altratech product and assay can rapidly detect and quantify molecular targets from any sample. The technology brings together nanotechnology, CMOS semiconductor technology and novel PNA chemistry to produce a unique and powerful assay. The assay named Molecular Detection by Proxy is a bead-based technology coupled with ultra-sensitive capacitance detection.

We are creating an infrastructure of technology and data to manage contagious viral diseases, important for the future of decentralised connected healthcare and wellbeing.

Based on the novel Detection by Proxy concept, Altratech has developed the next generation of molecular detection. The technology enables any person, anywhere, to rapidly and accurately measure and quantify viral RNA, DNA, antigen, or antibody samples.